FDA limits use of Johnson & Johnson’s Covid-19 vaccine, citing clotting risk
The Food and Drug Administration on Thursday announced it was limiting access to Johnson & Johnson’s Covid-19 vaccine because of the risk of a clotting disorder that was discovered weeks after the vaccine was first put into use in the spring of 2021.
The agency said that a review of the available data on the risk of thrombosis with thrombocytopenia — or TTS — suggested limiting access to the vaccine is warranted. The condition, though rare, can be fatal.
